Announcements Trials

Browse Landscape

Sponsor

Conditions

Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Mesothelioma 1 Melanoma 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 44 Gemcitabine 23 Nivolumab 21 enfortumab vedotin 20 Cisplatin 17 avelumab 16 Magnetic Resonance Spectroscopy 16 Carboplatin 14 atezolizumab 13 Specimen Handling 12 Docetaxel 11 sacituzumab govitecan 9 Paclitaxel 8 Ipilimumab 8 durvalumab 6 Mitomycin 5 Fluorodeoxyglucose F18 5 cabozantinib 4 Taxes 4 toripalimab 3 pemigatinib 3 erdafitinib 3 X-Rays 3 Radiosurgery 3 Platinum 3 Pemetrexed 3 Immunoglobulin G 3 CTLA-4 Antigen 3 Biopsy 3 ALT-803 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × naptumomab estafenatox × 1 year × Clear all

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡